External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

CMSC 2021

-
Coming soon
02:45 PM
Duration 12mins Virtual
A Description of Real-World MRI Acquired in Patients With Multiple Sclerosis: Preliminary Insights From FlywheelMS
Traboulsee A, Hanson G, Mace K, Tarsa S, Rovira A, Henry RG, Li DK, Gan R, Julian L, Goldberg J, Tsougarakis C, Belendiuk K, Gaetano L

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 12mins Virtual
Treating Minority Patients with Multiple Sclerosis: Development of the CHIMES Trial
Williams M, Amezcua L, Vartanian T, Wu GF, Monson N, Bernitsas E, Harp C, Jia X, Pei J, Acosta J, Magrini F, Reder AT

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:15 PM
Duration 12mins Virtual
Improvements in Work Productivity and Activity Impairment in Ocrelizumab▼-Treated Patients With RRMS: 2-Year Data from the CASTING Study
Comi G, Cutter G, van Wijmeersch B, Kister I, Poloz Y, Kuenzel T, Buffels R, Vermersch P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:15 PM
Duration 12mins Virtual
Recently Diagnosed Early-Stage RRMS: NEDA, ARR, Disability Progression, Serum Neurofilament and Safety: 1-Year Interim Data From the Ocrelizumab▼ Phase IIIb ENSEMBLE Study
Vollmer T, Freedman MS, Killestein J, Nos C, Vanopdenbosch L, Buffels R, Kadner K, Kuenzel T, Hartung HP, on behalf of the ENSEMBLE Investigators and Steering Committee

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar